TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Omacetaxine mepesuccinate

First Posted Date: 2006-09-12

Last Posted Date: 2021-11-15

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 103

Registration Number: NCT00375219

Locations: 🇺🇸
Teva Investigational Site 003, Los Angeles, California, United States
🇫🇷
Teva Investigational Site 029, Bordeaux, France
🇫🇷
Teva Investigational Site 021, Le Chesnay Cedex, France

and more 29 locations

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Phase 2

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: laquinimod 0.3
Drug: laquinimod 0.6
Other: Placebo

First Posted Date: 2006-07-06

Last Posted Date: 2011-04-08

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 306

Registration Number: NCT00349193

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Phase 3

Completed

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate (GA) 40 mg
Drug: glatiramer acetate 20 mg

First Posted Date: 2006-06-16

Last Posted Date: 2011-10-10

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 1155

Registration Number: NCT00337779

Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN Therapy

Completed

Conditions: Multiple Sclerosis

Interventions: Procedure: NAbs testing

First Posted Date: 2006-06-13

Last Posted Date: 2013-10-30

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 1230

Registration Number: NCT00336557

Locations: 🇺🇸
Neuro-Pain Medical Center, Fresno, California, United States
🇺🇸
Fullerton Neurology and Headache Center, Fullerton, California, United States
🇺🇸
East Bay Physicians Medical Group, Berkley, California, United States

and more 46 locations

Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Albuterol

First Posted Date: 2006-03-30

Last Posted Date: 2022-04-01

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 95

Registration Number: NCT00308685

Locations: 🇺🇸
Allergy & Asthma Specialist Medical Group, Huntington Beach, California, United States
🇺🇸
Little Rock Allergy and Asthma, Little Rock, Arkansas, United States
🇺🇸
Allergy & Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States

and more 9 locations

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

Phase 2

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: Talampanel
Radiation: Radiation Therapy (RT) 5 days a week +
Drug: temozolomide(TMZ) 75mg
Drug: adjuvant TMZ 200mg

First Posted Date: 2005-12-21

Last Posted Date: 2016-05-19

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 72

Registration Number: NCT00267592

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Rasagiline Mesylate
Other: Placebo

First Posted Date: 2005-11-21

Last Posted Date: 2012-01-12

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 1174

Registration Number: NCT00256204

Non-invasive Measures of Distal Lung Disease in Asthmatics

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Advair
Drug: QVAR
Drug: Servent Diskus

First Posted Date: 2005-11-08

Last Posted Date: 2021-12-02

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 34

Registration Number: NCT00250341

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: glatiramer acetate with placebo
Drug: glatiramer acetate injection with oral cetirizine hydrochloride

First Posted Date: 2005-10-17

Last Posted Date: 2011-04-11

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 80

Registration Number: NCT00240032

Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2005-10-05

Last Posted Date: 2021-11-12

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 15

Registration Number: NCT00232999

Locations: 🇨🇦
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
🇨🇦
Centre de cardiology et de pneumologie de l'Universite Laval, Sainte-Foy (Quebec City), Quebec, Canada
🇨🇦
University of Saskatchewan, Saskatoon, Saskatchewan, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy